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Abstract 
Objective: 
To determine response of low-IQ children with attention deficit hyperactivity disorder (ADHD) 
symptoms to methylphenidate (MPH). 
Methods: 
An aggregated analysis was conducted in 90 children with low IQ who received the same dose 
regimen of MPH in three independent, placebo-controlled studies. Active drug and placebo were given from 
2 to 4 weeks each. Outcome measures included teacher and parent ratings on standardized behavior scales 
(mean n = 84), performance on computer-controlled cognitive-motor tests (n = 62), and measures of 
cardiovascular response (n = 85). 
Results: 
Both teachers and parents rated the children consistently as being improved on subscales assessing 
attention, overactivity, and conduct problems. Some 44% of the subjects showed at least a 30% reduction 
compared with placebo on teacher ratings. MPH improved accuracy on several cognitive tests, response 
speed was increased on some, and seat activity declined for one of three tests; heart rate was mildly increased 
(3.9 beats/minute) with MPH. Analyses of IQ and mental age as moderator variables suggested that lower 
functional level (especially lower IQ) may be associated with a less favorable response to MPH. 
Conclusions: 
Children with low IQ and ADHD clearly respond to MPH, but their rate of beneficial response 
appears to be well under that of normal-IQ children and more varied. Different attentional mechanisms may 
moderate response to psychostimulants. 
Introduction 
It has long been known that the use of psychostimulants (e.g., methylphenidate [MPH], 
dextroamphetamine, and d-l-amphetamine) is the treatment of choice in normally developing 
children with attention deficit hyperactivity disorder (ADHD) (Barkley et al. 1999; Wilens and 
Spencer 2000). However, the earliest studies of psychostimulants in patients with mental 
retardation were often negative. Gadow (1985), who reviewed this literature, noted that presence 
of institutional environments, the choice of target symptoms often unrelated to ADHD, and 
frequent selection of subjects across the age span made interpretation of these studies very 
problematic. 
Since 1980, several good studies (all placebo controlled with crossover designs) have been 
conducted with children having both a developmental disability and ADHD. Hagerman et al. 
(1988) assessed dextroamphetamine (0.2 mg/kg) and MPH (0.3 mg/kg) in children with fragile X 
syndrome and attention deficit disorder (mean IQ = 58; range 29–77). Teacher ratings (but not 
parent ratings) showed significant benefit with MPH; 10 of the 15 subjects (67%) were considered 
responders to either MPH or dextroamphetamine. Handen et al. (1990) assessed MPH in doses of 
0.3 and 0.6 mg/kg in 12 children (mean IQ = 65; range 50–74). Teacher ratings on both the 
Conners’ Abbreviated Symptom Questionnaire (CASQ, sometimes called the Hyperkinesis Index) 
and the Conners’ Teacher Rating Scale (CTRS) showed reductions in attention problems, 
over-activity, and conduct problems at both doses. Handen et al. (1992) again compared placebo 
and 0.3 mg/kg and 0.6 mg/kg MPH in 14 children with ADHD (mean IQ = 66; range 48–74). Once 
again, ratings on the CASQ and CTRS consistently showed significant improvement with both 
doses of MPH. Handen et al. (1996) compared placebo and 0.3 and 0.6 mg/kg MPH in 44 children 
(mean IQ = 64.3; range 44–77); this report included children from Handen et al. (1992). Both 
active doses resulted in significant improvements on the CASQ, CTRS, and the Childhood 
Attention Problem Scale (Edelbrock 1978) as assessed by teachers. Pearson et al. (2003) recently 
reported a study of 24 children, with a mean IQ of 56.5, who received placebo and doses of 0.15, 
0.30, and 0.60 mg/kg MPH. As assessed by CTRS, CASQ, and the Attention Deficit Disorder with 
Hyperactivity Comprehensive Teacher’s Rating Scale (Ullmann et al. 1997), the high dose (0.6 
mg/kg) was consistently superior to placebo (82% of subscales), and the middle dose (0.3 mg/kg) 
was inconsistently superior (27% of the subscales). Only 1 of 19 parent-rated subscales was 
sensitive to medication, and this was confined to the high dose. 
Thus, most of the studies in the mental retardation field have used relatively low MPH 
doses in the range of 0.15 to 0.60 mg/kg, and most have been successful in showing beneficial 
changes in behavioral indices of attention and activity. Arnold et al. (1998) reviewed these and 
other studies in children with developmental disabilities, and they noted that the psychostimulants 
are clearly an effective treatment for co-occurring ADHD symptoms. Aman (1996) also reviewed 
this literature, concurred about overall drug response, and observed that clinical response was 
more heterogeneous in children with mental retardation (with a response rate around 55%) than in 
normal-IQ children, possibly lower still in children with autistic disorder (see also Aman and 
Langworthy 2000). However, to forecast an issue that is discussed in more detail later in this 
article, there are reasons to believe that children with mental retardation and ADHD may be more 
prone to adverse effects than typically developing children with ADHD. 
Our group has completed three independent studies (with about 30 subjects each) of MPH 
in children with low IQs (Aman et al. 1991, 1993, 1997). Certain procedures, including choice of 
drug, dosing regimen, and assessments, were held constant across these studies. The prevalence of 
mental retardation is about 1%, and the co-occurrence of fullblown cross-situational ADHD 
symptoms in addition to mental retardation is uncommon (perhaps 10–12%) (Benson and Aman 
1999). Hence, the 90 participants having such low IQ and hyperactivity provide an opportunity to 
study the largest such sample ever assembled for research of these targets. In this report, we 
present an aggregate analysis of common variables collected in the three studies. 
Methods 
Subjects 
Study 1. 
The participants were 32 New Zealand children and adolescents attending special schools, 
special classes, or special resource classes for children with mental retardation. Age ranged from 4 
to 17 years (mean = 10.1, SD = 3.1 years). IQs ranged from unmeasurable to 90 (mean = 52.8, SD 
= 20.3). There were 27 boys (84.4%) and 5 girls (15.6%). Ethnicity was as follows: Caucasian (n = 
22, 68.8%), New Zealand Maori (n = 6, 18.8%), and Pacific Islander (n = 4, 12.5%). 
Entry criteria required each child to meet Diagnostic and Statistical Manual of Mental Dis-
orders, third edition (DSM-III; American Psychiatric Association 1980) criteria for attention 
deficit disorder (ADD) (n = 29) or conduct disorder (CD) (n = 1) or both ADD and CD (n = 2). 
Rating scales completed by parents and teachers and a structured interview using the Diagnostic 
Interview Schedule for Parents (DISC-P) (Shaffer et al. 1989, unpublished manuscript) along with 
a clinical interview supported the diagnosis. Twenty-four of the subjects met DSM-III criteria for 
attention deficit disorder with hyperactivity (ADD-H). Four were diagnosed as having attention 
deficit disorder without hyperactivity, and one had attention deficit disorder, residual type. Three 
participants had a conduct disorder, and one child had pervasive developmental disorder not 
otherwise specified (PDD-NOS) in addition to ADD-H. Other than conduct disorder, autistic 
disorder, and PDD-NOS, the participants were not screened for additional DSM disorders. 
Study 2. 
The subjects were 28 American children, aged 5 to 13 years (mean age = 8.8, SD = 2.6 
years). There were 20 boys (66.7%) and 8 girls (33.3%). The children’s IQs ranged from 
untestable (2 children) to 78, with a mean of 61.0. There were three African American and 25 
Caucasian children in this group. Inclusionary criteria were the following: (a) IQ ≤ 80, (b) 
presence of severe inattention or hyperactivity as assessed on the CTRS (i.e., exceeding 90th 
percentile on the Inattention or Hyperactivity subscales relative to norms), (c) presence of severe 
inattention or motor excess as rated by parents on the Revised Behavior Problem Checklist 
(RBPC; Quay and Peterson 1987) (i.e., exceeding the 90th percentile on these subscales), (d) 
professional diagnosis of ADHD based on DSM-III-R criteria (American Psychiatric Association 
1987), and (e) aged between 5 and 13 years. Exclusion criteria included the following: (a) motor 
handicap, (b) autism or symptoms of psychosis, (c) epilepsy, and (d) Down syndrome (excluded 
because Down syndrome was thought to be a possible contraindication for one of the two study 
drugs, fenfluramine). 
Study 3. 
The inclusionary and exclusionary criteria were the same as for study 2, with some minor 
exceptions. First, age extended from 5 to 14 years. Second, the upper limit for IQ was 84 rather 
than 80. Otherwise all criteria were identical. In all, 35 children participated. Five of these were 
dropped because of noncompliance with the protocol. There were 22 boys and 8 girls. Mean age 
was 7.7 years (SD = 2.5 years). There were 5 African American subjects (16.7%), 1 Hispanic 
(3.3%), 1 Asian (3.3%), 21 Caucasian (70.0%), and 2 (6.7%) with mixed ethnicity (African 
American and Caucasian). IQs extended from the basal score (36) to 84, with a mean of 61.8 (SD 
= 13.63). We did not attempt to do formal psychiatric diagnoses for comorbidity, but the 
participants’ parents did complete the Stony Brook Checklist-3R (Gadow and Sprafkin 1987, 
unpublished manuscript), a screening instrument based on DSM-III-R criteria. The numbers 
screened for each comorbid disorder were as follows: conduct disorder (n = 7), oppositional 
defiant disorder (n = 3), overanxious disorder (n = 2), and separation anxiety disorder (n = 6). Two 
of the children had PDD-NOS. 
Combined sample. 
When all three samples were combined, we had a pooled sample of 90 children, with an 
age range extending from 4 to 17 years (mean = 9.0, SD = 2.9 years). IQ ranged from untestable to 
90, with a mean of 58.5 (SD = 16.1). Mental age extended from 1.9 to 9.9 years (mean = 4.9, SD = 
1.87 years). There were 69 boys (76.7%) and 21 girls (23.3%). Ethnicity was as follows: African 
American (n = 8, 8.9%), Asian (n = 1, 1.1%), Caucasian (n = 68, 75.6%), Hispanic (n = 1, 1.1%), 
Maori (n = 6, 6.7%), Pacific Islander (n = 4, 4.4%), and mixed (African American and Caucasian) 
(n = 2, 2.2%). Almost all of the children were in special educational placements, usually in 
classrooms designated for children with mental retardation. Furthermore, although nine of these 
children currently tested above the mentally retarded range (i.e., above 75), most of these had at 
some previous time been found to have mental retardation as assessed on IQ and adaptive behavior 
scales (e.g., one child in Aman et al. 1993; five children in Aman et al. 1997). After complete 
description of the study to the parents, written informed consent was obtained. A multitude of 
events (e.g., the winter blizzards of 1994 and failure of teachers to mail forms) and some outliers 
(see the Data Analysis section) caused some data loss. In addition, only about 70% of subjects 
could perform the cognitive tests. As a result, the mean sample size for the clinical (rating scale) 
measures was 84, for cardiovascular measures 85, and the mean sample size for the cognitive tests 
was 62. 
Design 
All three studies employed crossover designs, and all three included a double-blind 
comparison of placebo, MPH (0.40 mg/kg) given in the morning only, and another drug. This 
standardized dose of MPH was selected because previous studies in typically developing children 
suggested that the dose fell midway between an optimal dose for performance on a short-term 
memory task (i.e., 0.3 mg/kg) and behavior (i.e., around 0.70 mg/kg) (Sprague and Sleator 1973, 
1977). Not all attempts to replicate these dose response curves have been successful (see Richters 
et al. 1995). 
Study 1 was a comparison of placebo, MPH, and thioridazine (Mellaril, USA) given in 
divided daily doses of 1.75 mg/kg. Each drug condition was given for 3 weeks. Study 2 was a 
comparison of placebo, MPH, and fenfluramine (Pondimin, USA) given in divided daily doses of 
1.50 mg/kg/day. All three conditions were given for 4 weeks each. Study 3 was a comparison of 
placebo, MPH, and three doses of fenfluramine (1.0, 1.5, 2.0 mg/kg/ day) given in divided daily 
doses. Each medication was given for 2 weeks. Studies 1 and 2 used Latin square designs to 
balance drug order and time; there were three drug orders for each study. Study 3 used two 
mirror-image Latin squares, and each drug condition appeared equally often at each possible time 
point. 
Thus, all participants received placebo and the same dose of MPH, given in the same 
regimens (once daily, administered before going to school). The order of medication (placebo first, 
MPH second, and vice versa) was balanced, although sometimes comparator medicines were 
administered between them. Equal numbers of children received placebo first and MPH second 
and vice versa. There were no interactions in these studies between drug order and drug effect on 
any of the outcome variables showing a significant drug effect. On the last day of each drug period, 
all subjects were brought by their parents to the laboratory for standardized assessments, which 
included parent ratings, heart rate and blood pressure assessment, and evaluation of cognitive 
performance using computer-controlled equipment. These assessments were usually begun 60 to 
90 minutes after morning medication. 
Measures of drug change 
With the exception of the Aberrant Behavior Checklist (ABC; Aman et al. 1985), all 
variables described below were used in all three studies. The ABC was used only in studies 2 and 
3. 
Behavioral measures. 
The children were rated by their teachers on the CTRS (Conners 1969) and the ABC 
(Aman et al. 1985). The 39-item CTRS was developed by factor analysis with typically developing 
children; it has four subscales: Conduct Problem, Inattention, Tension/Anxiety, and Hyperactivity. 
Furthermore, we derived a score for the CASQ from the CTRS. The CASQ is a 10-item 
instrument, comprising items related to ADHD and emotionality, that has often been used in drug 
research (Aman and Pearson 1999; Goyette et al. 1978). The ABC was developed by factor 
analysis with children and adults having mental retardation. Its five subscales are designated as: 
Irritability, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/ Noncompliance, 
and Inappropriate Speech. 
Parents rated their children on the Revised Behavior Problem Checklist (RBPC), an 
89-item instrument also developed by factor analysis with typically developing children (Quay 
and Peterson 1987). Its six subscales were designated as follows: Conduct Problem, Socialized 
Aggression, Attention Problem, Anxiety/Withdrawal, Psychotic Behavior, and Motor Excess. The 
RBPC has frequently been used in clinical research, especially that involving conduct and 
aggressive disorders, but it has not been frequently used in drug research (Aman and Pearson 
1999). Because we did not regard the Socialized Aggression subscale as relevant for many of our 
participants, we deleted the items from this subscale. Parents also rated their children on the CASQ 
and on the ABC described earlier. 
Cardiovascular. 
Each time the children visited the laboratory, their radial heart rate and blood pressure were 
monitored by a physician with the subject seated following a 5-minute period of rest. 
Cognitive performance and activity level. 
Each time the subject visited the laboratory, he or she was assessed on a cognitive battery 
that was mostly computer controlled. There is a body of psychometric data on all of the 
performance measures used. Each of the tests has adequate reliability, validity, and drug 
sensitivity to be a useful measure of treatment outcome (see Aman 1991). The following tests were 
included. 
1. Matching to Sample (MTS) task: The MTS task was developed to assess memory in 
pigeons (Cumming and Berryman 1965). We adapted it for use in children with low IQ. 
Our version involved the repeated presentation of three colors: red, yellow, and blue. One 
color was presented at the center-top of the screen. The subject then pressed the screen to 
indicate that he or she saw the stimulus. One second later, the colors red, yellow, and blue 
were displayed at the bottom of the screen. The child’s job was to locate the color that 
matched that previously seen and to press that part of the screen. Each time the child got 
three consecutive trials in a row correct, the computer added 1.0 second to the delay 
between the test stimulus and the response stimuli. Each time the subject erred, the 
computer subtracted 1.0 second, down to a minimum of 1.0-second delay. Four measures 
were derived from this task: accuracy, longest delay achieved, mean delay, and mean 
response time (time for subject to decide and press the screen). 
2. Matching Familiar Figures (MFF) task: The MFF task is said to measure the subject’s 
ability to pause and reflect on a complex problem, but the task clearly also tests the ability 
to perceive minor differences between stimuli (Aman 1991; Kagan 1965). In our version of 
the MFF task, a probe stimulus was presented at the center-top of the screen, and four test 
stimuli were simultaneously presented across the bottom of the screen. All of the figures 
were drawn to be quite similar, but only one of the four stimuli at the bottom was identical 
to the one at the top. The child’s task was to find the test stimulus that matched the probe 
and to push the button corresponding to that stimulus. Two variables were collected, 
namely, accuracy (percent correct) and response time. 
3. Continuous Performance Task (CPT): The CPT used in this study employed two pictures, 
one of a princess and one of a witch (Aman 1991). The child was told to warn the princess 
by pressing a lever when the witch appeared and to refrain from responding when the 
princess appeared on the screen. This test of attention span took about 8 minutes to 
complete. There were 162 trials in all, 40 of which were the target (i.e., witch). The 
variables included failures to detect the witch (omission errors), incorrect detections when 
the princess was displayed (commission errors), and mean response time. 
4. Seat Movement: The chair on which children sat was equipped with a pivot at its center and 
a microswitch under each of the sides (Aman 1991). Each tilt of the seat resulted in closure 
of one of the microswitches, which was automatically recorded by the computer. Only 
activity occurring during the constant (computer-controlled) portions of the test was 
recorded. All tests listed here have been described much more fully in Aman (1991). 
Data analysis 
Prior to inferential analyses, the data were examined for the presence of outliers and 
deviations from normality. The data screening occurred in a two-step process. First, extreme 
values (defined by SPSS [Statistical Package for the Social Sciences, Version 9.0, computer 
software, Chicago SPSS, 1998] as 3 times the interquartile range—the distance between the first 
quartile [25th percentile] and third quartile [75th percentile]) were identified for each variable and 
then excluded. Next, data were checked for degree of skew. When skewed, data were transformed 
using a square root, logarithmic, or inverse transformation, depending on the degree of skew 
(criteria: skew < 0.8, no transformation; skew 0.8–1.5, square root; skew 1.5–3.0, logarithmic; 
skew > 3.0, inverse). The type of transformation, if present, is presented after each variable (S = 
square root, L = logarithmic, I = inverse). All such transformations were performed and outliers 
removed before any data analyses were conducted. 
For the main analysis, we used an analysis of variance (ANOVA) model, and we assessed 
for the effects of (a) study (1, 2, or 3; between-subjects factor) and (b) drug (placebo vs. MPH; 
within-subject factor). We also conducted secondary analyses to see if IQ or mental age had 
significant effects on outcome. For these analyses, we used a three-way ANOVA model and 
analyzed as a function of (a) either IQ (greater than/less than 50) or mental age (greater than/less 
than 4.5 years) (between subjects), (b) study, and (c) drug. 
Results 
Because of the number of variables assessed, we set alpha at p = 0.01. Because there are so 
few reports on stimulant effects in children with mental retardation, we identified changes at the 
0.05 level of significance to enable readers to make exploratory comparisons (see Tables 1 and 3). 
Behavioral changes 
Results for the teacher and parent ratings are presented in Table 1. In general, subscales 
assessing attention problems and motor excess showed a significant advantage for MPH over 
placebo. There were only two minor exceptions (no effect for attention problem on the RBPC and 
parent CASQ). Although MPH was only given once a day, both teachers and parents were reliable 
in detecting differences between drug and placebo. 
We derived a definition of responder by using teacher ratings on the CASQ to calculate 
response rate. We did this by calculating the number of children to show improvement in 10% 
increments using the following formula: (Placebo 2 MPH)/Placebo. Table 2 shows the rates of 
clinical response for various criteria (20% improvement, 30% improvement, etc.). If we arbitrarily 
classify children who showed more than 30% improvement as responders, then 36 of 81 children 
(45%) were responders. Another way to gauge change is to examine effect sizes, which were 
calculated for significant subscales related to inattention or overactivity. For teachers, the effect 
sizes were: CTRS Inattention, 0.46; CTRS Hyperactivity, 0.69; CASQ, 0.56; and ABC 
Hyperactivity, 0.58 (mean = 0.57). For parents, the effect sizes were usually smaller: RBPC Motor 
Excess, 0.26; ABC Hyperactivity, 0.35; and Global Rating, 0.56 (mean = 0.39). 
Results from the cognitive tests are presented in Table 3. All significant changes (6 of 13; 
46%) indicated improvement with MPH. On the MTS task, subjects had greater accuracy and 
shorter response times with MPH. On the CPT, both errors of omission and errors of commission 
were greatly reduced (by 40.0% and 49.6%, respectively); response time was significantly reduced 
as well. Seat movement was significantly reduced only during the CPT (by 33.6%). 
Cardiovascular changes 
Heart rate was increased with MPH (3.9 beats/minute); the increases in diastolic and 
systolic blood pressure just failed to reach the 0.01 level of significance (2.9 and 2.1 mm Hg, 
respectively). 
Secondary analyses: Subject variables associated with clinical response 
In an effort to determine if there were useful subject variables that helped to predict clinical 
outcome, we divided the subjects by mental age (<4.49 or ≥4.50 years) and by IQ (<49 or ≥50). 
These division points were chosen because they were very close to the median 
Table 1. Effects of Methylphenidate on Clinical Variables 
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normal-ability children (Arnold 2000; Barkley 1998; Greenhill et al. 2001; The MTA Cooperative 
Group 1999), although the dosage difference may account for some of the difference in response. 
The effect sizes observed here (mean Cohen’s d of 0.57 for teachers and 0.39 for parents) were 
clearly smaller than those seen in typically developing children (usually at least 0.80 and 0.70 for 
teachers and parents, respectively). For instance, the MTA Cooperative Group (Greenhill et al. 
2001), in the placebo-controlled titration of 270 children, found effect sizes of 0.9 for teacher and 
0.8 for parent ratings. 
Our standardized dose of 0.4 mg/kg given once daily was clearly below average doses used 
in typically developing children with ADHD (Arnold 2000; The MTA Cooperative Group 1999), 
and it may have been suboptimal for many participants. Nevertheless, parents were able to detect 
MPH’s effects, despite the fact that the drug was given only in the morning and although only 
minor drug effects may have been visible after the school day. It is quite possible that MPH (as 
well as other drugs) may have to be given in more conservative doses in patients with 
developmental disabilities, as suggested elsewhere (Arnold et al. 1998). Handen and associates 
found high rates of side effects (e.g., dysphoria, tics, lack of social responsiveness) in such 
children, especially with 0.6 mg/kg, the higher of two doses used (Handen et al. 1991; 2000). In 
one study, medication needed to be discontinued for 6 of 27 children (22%) with developmental 
disabilities because of motor tics or severe social withdrawal; 2 children with social withdrawal 
were not exposed to the larger of two planned MPH doses (0.3 and 0.6 mg/kg), and the higher dose 
needed to be discontinued for another child who developed severe irritability (Handen et al. 1991). 
In a study of 11 preschoolers with developmental disabilities, 5 of 10 children (50%) experienced 
serious side effects (primarily irritability and social withdrawal) at the 0.6-mg/kg MPH dose (0.3 
and 0.6 mg/kg were used) (Handen et al. 1999). The higher dose was not given to an additional 
child who experienced irritability, crying, and anxiety at 0.3 mg/kg. Furthermore, although our 
doses were conservative, they were also internally consistent across all children assessed here. 
Thus, the more heterogeneous response in the lower IQ children cannot be considered to be merely 
a vagary of the dosing procedure. 
Whereas IQ less than 50 was associated with a more heterogeneous response than found in 
higher-functioning children, we do not feel that this should preclude clinical trials in 
lower-functioning children. With the exception of one child with PDD-NOS who began to bite his 
wrist while taking MPH (Aman et al. 1991), we can recall no other child who showed severe side 
effects with the drug at this low dose. Hence, psychostimulants are often still worth a try in such 
youngsters, starting with a low dose and titrating cautiously. 
Effects on cognitive-motor variables 
The pattern we observed here was very much in keeping with what has been found in 
typically developing ADHD children, with the greatest effects observed in attentional variables 
(Aman 1978; Barkley et al. 1999; Douglas and Peters 1979) and in motor activity (Barkley 1998; 
Sprague and Sleator 1973, 1977; Werry and Aman 1975). Thus, the mechanism of change appears 
to be quite consistent regardless of clinical group. However, it is interesting that the significant 
decreases in seat activity were confined to the CPT, suggesting considerable task specificity in 
motor overflow. 
Factors associated with drug response 
As noted earlier, higher IQ and (for some variables) higher mental age were sometimes 
associated with a better drug response. This is consistent with one hypothesis that attentional 
variables may moderate clinical response for some children (Aman 1982, 1996; Aman and 
Langworthy 2000). However, other explanations may account for these associations better, and 
not all attempts to predict outcome by reference to IQ have observed a relation (e.g., Handen et al. 
1994; Mayes et al. 1994). 
Conclusions 
To sum up, it is clear that MPH is effective in children with low IQ and ADHD symptoms, 
especially with IQ down to 50. At the same time, stimulants do not appear to work as well in such 
children as in children with normal IQ and ADHD. This may be reflected both in the number of 
responders and in the magnitude of response. In a review of the mental retardation and 
developmental disabilities literature (Aman 1996), an overall response rate of 54% was found. 
Although this may not be as good as the frequently cited figure of 65–75% for children with 
normal IQ, this is still a reasonable probability of response with a drug that has relatively few side 
effects. 
The observation that psychostimulants were less successful in patients with lower mental 
age and IQs of below 50 may be consistent with a lower rate of response in preschoolers with 
ADHD (Arnold 2002). By definition, preschoolers have lower mental ages than school-age 
children. Nevertheless, even in children with low IQ/low mental age, psychostimulants (because 
of their favorable side-effect profile) are still worth serious consideration in children with 
prominent ADHD. However, clinicians may wish to employ lower test doses in certain cases 
considered to be at high risk (e.g., those with severe self-injury, stereotypic behavior, or severe 
autism). 
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